How Agilent’s PD-L1 companion diagnostic now shapes pembrolizumab access in esophageal carcinoma
FDA approves Agilent's PD-L1 IHC 22C3 pharmDx for esophageal and GEJ carcinoma, marking the eighth companion diagnostic indication alongside pembrolizumab. Read the analysis.